Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Approval on a knife edge.

× No keyword cloud information.

5 in total

1. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Authors: Sandra V Navarra; Renato M Guzmán; Alberto E Gallacher; Stephen Hall; Roger A Levy; Renato E Jimenez; Edmund K-M Li; Mathew Thomas; Ho-Youn Kim; Manuel G León; Coman Tanasescu; Eugeny Nasonov; Joung-Liang Lan; Lilia Pineda; Z John Zhong; William Freimuth; Michelle A Petri
Journal: Lancet Date: 2011-02-04 Impact factor: 79.321

2. The discovery and development of belimumab: the anti-BLyS-lupus connection.

Authors: William Stohl; David M Hilbert
Journal: Nat Biotechnol Date: 2012-01-09 Impact factor: 54.908

3. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.

Authors: Michelle Petri; William Stohl; Winn Chatham; W Joseph McCune; Marc Chevrier; Jeff Ryel; Virginia Recta; John Zhong; William Freimuth
Journal: Arthritis Rheum Date: 2008-08

4. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

Authors: Daniel J Wallace; William Stohl; Richard A Furie; Jeffrey R Lisse; James D McKay; Joan T Merrill; Michelle A Petri; Ellen M Ginzler; W Winn Chatham; W Joseph McCune; Vivian Fernandez; Marc R Chevrier; Z John Zhong; William W Freimuth
Journal: Arthritis Rheum Date: 2009-09-15

Review 5. Emerging biological therapies in systemic lupus erythematosus.

Authors: G R Mount; W R Gilliland
Journal: Clin Pharmacol Ther Date: 2007-11-14 Impact factor: 6.875

5 in total

3 in total

Approval on a knife edge.

1. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

2. The discovery and development of belimumab: the anti-BLyS-lupus connection.

3. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.

4. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

Review 5. Emerging biological therapies in systemic lupus erythematosus.

1. Lupus in crisis: as failures pile up, clinicians call for new tools.

Review 2. Rituximab: how approval history is reflected by a corresponding patent filing strategy.

Review 3. Immune checkpoint receptors in regulating immune reactivity in rheumatic disease.